Vertex Spends $10 Billion to Buy Crinetics, Making Rare Endocrine Diseases the Next Battleground
The deal is not only a financial move by a large pharmaceutical company to strengthen its pipeline. It also shows that rare endocrine diseases are moving from a niche market toward a more competitive, more capital-intensive stage for new drug development.